What's new?

• Sofinnova Crossover Fund 1 is the largest healthcare crossover fund focused on Europe.
• With this new fund, Sofinnova Partners actively pursues the strategy to broaden its Life Sciences platform to invest across the value chain, from seed stage to late-stage companies.
• Bpifrance* and CNP Assurances acted as sponsors for the fund.

Paris, France – April 4th, 2018 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today the launch of Sofinnova Crossover I with €275 million ($340 million), above the original first close target of €250 million. With this new fund, Sofinnova Partners goes one step further in the execution of its growth plan, aimed at expanding its coverage across the Life Sciences space with dedicated sector teams.

Pursuing a strategy Sofinnova Partners has successfully applied for decades with its early-stage focused Capital Funds, Sofinnova Crossover I will invest in the biopharmaceutical and medical device sectors. The fund will focus primarily on therapeutic and game-changing companies driven by experienced management. As a lead or cornerstone investor, the fund will seek to invest in about 15 late stage private and public companies. About 80% of the investments will be made in European companies, with the remaining 20% outside of Europe primarily in North America. A dedicated, highly experienced team of four partners will invest Sofinnova Crossover I, leveraging on Sofinnova Partners’ wider experience, track record and organizational support. This new fund attracted premier international investors, predominantly sovereign funds, insurance companies, corporations and family offices. Commitments came from Europe, including France, Italy, Denmark, Ireland, and Switzerland but also from Asian investors in China and Singapore. In addition to Bpifrance* and CNP Assurances, investors include a major Chinese biopharmaceutical company, the Danish State Investment fund, and family offices like Fidim or KCK representing leading industrial families in Europe and Asia.

Antoine Papiernik, Chairman of Sofinnova Partners, said, “With the launch of this new crossover activity, Sofinnova builds upon its unique early stage track record. Many of the companies we initially funded have become over the years large, billion-euro companies, and we have gained invaluable experience in helping them to the next level. This fund will complete our investment platform across the life-sciences value-chain, allowing us to fund companies from the seed stage to the late-stage.”

Jacques Theurillat, Partner in the crossover team at Sofinnova Partners, added: “The European healthcare market has matured with hundreds of late stage private and public companies looking for growth capital, and Sofinnova Partners, with its name, track record and experience, is particularly well positioned to identify the best European deals and transform them into global leaders.”

Triago acted as placement agent and Clifford Chance Europe LLP acted as legal counsel on Sofinnova Crossover I.

* Bpifrance directly and with the “Investment for the Future” Program, managed by the SGPI and operated by Bpifrance

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead investor in start-ups and corporate spin-offs and has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management.


Biolipox, the Stockholm-based biotechnology company, has just closed a financing round of nearly €5 million with investments from the Swedish venture capital fund HealthCap and Paris based Sofinnova Partners. Antoine Papiernik, General Partner with Sofinnova Partners, joins the board of Biolipox.

The company was formed in 2000 by two scientists, Professors Hans-Erik Claesson and Magnus Bjorkholm from the Karolinska Institute, and is specialized in the discovery and development of new therapeutic compounds for use in the treatment of respiratory diseases and other inflammatory pathologies.

Biolipox had received at the time of the company’s formation a first seed investment of €0.6 brought in by HealthCap. The current investment round is expected to finance the company’s research program through the end of 2002. Biolipox is working on a new metabolic pathway of arachidonic acid, one of the most important and efficient of the fatty acids, which are essential components of diet. The two metabolic pathways already identified have resulted in the development of such vital compounds as aspirin, Cox2 or leucotriene inhibitors. Bengt Samuelson, who won the Nobel Prize for Medicine for his work on prostaglandins and leucotrienes whilst in the same department of the Karolinska Institute, and who is currently the chairman of the Nobel Foundation, sits on the company’s board of directors.

This discovery could result in the development of more specific drugs with the potential to become blockbusters in the treatment of asthma and other inflammatory respiratory diseases. The pharmaceutical products market for the treatment of respiratory diseases (in particular asthma) was estimated at USD 8.5 billion in 1999. There is currently a considerable need for the development of new therapeutic compounds to be used for the acute or chronic treatment of asthma sufferers.

"The quality of the investors that are backing the company confirms the view that Biolipox is a good investment opportunity. The close relationship between the company, its managers, and the Karolinska Institute, which is considered a world-leader in respiratory pathologies, is a further illustration of the importance of the project developed by Biolipox" stated Dr Carl-Johan Daalsgard, MD PhD, Chief Executive Officer of Biolipox, who has worked many years at the Karolinska Institute and as a senior manager with the pharmaceuticals group Astra.

According to Antoine Papiernik, General Partner with Sofinnova Partners, "Biolipox has all the characteristics we look for when financing a start-up: a prestigious team from one of the best academic centers in the world, a discovery of fundamental importance with multiple applications, strong intellectual property rights, and solid financial backing capable of seeing the company through to realization of its plans. Biolipox is also our first investment in Sweden. Until now, we have invested successfully in the UK, Italy, Switzerland, Germany, and of course France. Sweden now appears to us as a country where we can create major biopharmaceutical companies. Furthermore, we consider HealthCap as a top-tier investor in Nordic countries. We have previously worked with them in other company boards, and share similar investment strategies"

Sofinnova Partners, based in Paris since 1972, is a venture capital fund specialized in financing high-potential projects at an early stage of their development. Since its formation, it has supported companies in two specific sectors: life sciences and information technology. It is managed by seven partners and associates and has close to FRF 3 billion of funds under management. In the life sciences field, it favors investments related to bio-pharmacy and medical instrumentation and, notably, was a founder-investor in companies such as Genset, Cerep, NicOx, Actelion and NovusPharma. Sofinnova Partners has made 50 investments since 1996, of which 31 as the lead investor.


Antoine Papiernik General Partner Sofinnova Partners 17 rue de Surène 75008 Paris France Tel: 33 1 53 05 41 00 Fax: 33 1 53 05 41 29 Email: apapiernik@sofinnova.fr Web: http://sofinnova.social-unit.fr/
Carl-Johan Dalsgaard, CEO Biolipox AB, c/o Healthcap Sturegatan 34 Stockholm, Sweden Tel: 46 70 975 98 63

Visit website http://www.orexo.com


Sofinnova Partners, un des leaders français et européen du capital-risque
spécialisé dans les technologies de l’information et les sciences de la vie, a
levé 330 millions d’euros pour son nouveau fonds Sofinnova Capital IV.
L’objectif initial de la société, qui était de réunir 230 millions d’euros, a
été largement dépassé, compte tenu de la forte demande des investisseurs de ses
précédents fonds et, également, de nouveaux investisseurs.

Parmi les investisseurs de Sofinnova Capital IV, plusieurs investisseurs
importants des fonds précédents ont réinvesti : JP Morgan, AGF, HarbourVest
Partners, Swiss Re, Fondinvest, Dresdner Kleinwort Benson. Mais Sofinnova
Capital IV compte également de nouveaux investisseurs financiers (PartnersGroup,
LGT…) et industriels (IBM, Dow Chemical…) ainsi que des investisseurs privés,
dont plusieurs fondateurs d’entreprises financées par Sofinnova Partners.

Il s’agit du montant le plus élevé réuni par un capital-risqueur indépendant
en Europe depuis de longs mois, dans un environnement de marché pourtant peu
favorable. En 1998, lors de la clôture de son précédent fonds, Sofinnova Capital
III, Sofinnova Partners avait levé 120 millions d’euros, dont 60% ont été
investis au 31 mars 2001 dans trente entreprises.

Jean-Bernard Schmidt, Président de Sofinnova Partners, a déclaré : “Le succès
de cette levée de fonds, témoigne de la confiance des investisseurs à notre
égard, récompense le professionnalisme et le sérieux de notre équipe. Nous
sommes, depuis de nombreuses années, des bâtisseurs d’entreprises innovantes aux
côtés de leurs créateurs. Nos choix d’investissement sont, dans une proportion
élevée, couronnés de succès. Ce nouveau fonds nous donne les ressources
nécessaires pour continuer à investir dans des entreprises européennes
prometteuses, tant dans les sciences.de la vie que dans les technologies de
réseaux. Il nous conforte dans notre position d’acteur européen incontournable
du capital-risque”.

Une stratégie d’investissements ciblée et sélective

– L’objectif de Sofinnova Capital IV est d’investir dans trente nouvelles
entreprises pour des montants cumulés de 8 à 12 M d’euros par entreprise, en
plusieurs tours de financement.

– Les investissements se répartiront de façon équitable entre les deux
secteurs dans lesquels Sofinnova Partners s’est spécialisé depuis 1989 :
technologies de l’information et sciences de la vie. ¨ Dans le droit fil de la
stratégie de Sofinnova Partners, le nouveau fonds concentrera ses
investissements sur des projets d’amorçage, de création et de post-création

– Dans le domaine des technologies de l’information, Sofinnova Partners
financera en priorité des projets liés aux technologies de réseaux, un marché
appelé à capter les deux tiers des investissements en technologies de
l’information d’ici 2004.

– En sciences de la vie, Sofinnova Capital IV continuera à se concentrer sur
deux domaines essentiels : la biopharmacie visant des pathologies majeures comme
les maladies du système nerveux central, les maladies infectieuses ou le cancer
et des projets d’instrumentation médicale susceptibles de devenir des standards

– Sofinnova Capital IV sera investi à hauteur de 50% en France, de 35% dans
les autres pays d’Europe et 15% aux Etats-Unis.

Six investissements déjà réalisés

Dans le cadre de ce nouveau fonds, l’équipe de Sofinnova Partners a déjà
procédé à six investissements.

. Quatre d’entre eux concernent les sciences de la vie :

-> Neuro 3D, entreprise française développant des molécules dans le
domaine des maladies du système nerveux central, dont elle a financé l’amorçage
et a été co-leader du premier tour de table en novembre 2000 (1.3M d’euros).

->Cellzome, entreprise allemande de protéomique issue du prestigieux
centre EMBL de Heidelberg, dans laquelle elle a investi 5.6M d’euros en Février

->Biolipox, entreprise suédoise spécialisée dans la découverte et le
développement de nouvelles molécules thérapeutiques dans les maladies
respiratoires dans laquelle elle est intervenue en tant que co-leader du premier
tour de table à hauteur de 2.3 M d’euros en mars 2001

->David Pharmaceuticals, entreprise américaine spécialisée dans le
développement de nouvelles molécules thérapeutiques pour le traitement des
pathologies de la mémoire, dans laquelle elle est intervenue à hauteur de 3,3 M
d’euros, en tant qu’investisseur co-leader avec Sofinnova Ventures à San

. Deux autres investissements concernent les technologies de l’information :

->e-mail Vision, entreprise française fournissant une plate-forme
logicielle pour la mise en œuvre de campagnes de marketing direct sur Internet,
dans laquelle elle a investi 3.5M d’euros en mars 2001 en tant que leader d’un
nouveau tour de financement

->T-Source, nouveau fonds d’amorçage dans les télécommunications
d’I-source gestion, dans lequel elle a investi 2M d’euros en mars 2001

Sofinnova Partners, dont l’origine de l’activité remonte à 1972, est dirigée
par une équipe de 7 investisseurs solidaires et complémentaires issus d’horizons
extrêmement divers et organisés en deux pôles spécialisés (sciences de la vie et
technologies de l’information). Cette équipe s’appuie, pour son développement
international, sur un réseau européen de partenaires-investisseurs de premier
plan et pour les Etats-Unis sur son partenaire naturel, Sofinnova Ventures à San
Fransisco. L’équipe gère actuellement 500 M d’euros de fonds actifs.


Sofinnova Partners, one of the leading French and European venture capital
firms specializing in information technologies and life sciences, has raised EUR
330 million for its new Sofinnova Capital IV fund. The initial objective of EUR
230 million was surpassed because of strong demand from investors in previous
Sofinnova funds as well as from new investors.

Important investors in previous funds, such as JP Morgan, AGF, HarbourVest
Partners, Swiss Re, Fondinvest, and Dresdner Kleinwort Benson, have also
invested in Sofinnova Capital IV. It has also attracted new investors, both
financial (including PartnersGroup and LGT) and industrial (IBM, Dow Chemical
and others) as well as private investors, including founders of companies
financed by Sofinnova Partners.

This is the largest amount raised by an independent European venture capital
fund for many months and takes place in a market environment that is not exactly
favorable. In 1998, when it closed its previous fund, Sofinnova Capital III,
Sofinnova Partners had raised EUR 120 million, of which 60% had been invested as
of March 31, 2001 in 30 companies.

According to Jean-Bernard Schmidt, Managing Partner of Sofinnova Partners,
“the success of this fund raising exercise is a witness to investors’ confidence
in Sofinnova Partners, and rewards the professionalism and dedication of our
management team. For a number of years, we have built innovative companies by
working alongside their founders. A high proportion of our investment selections
have met with success. This new fund gives us the resources to continue
investing in promising European companies in both the life sciences and network
technologies fields. It strengthens our position as a leading European venture
capital player”.

A targeted and selective investment strategy

– Sofinnova Capital IV aims to invest EUR 8-12 million each in 30 new
companies, spread over several rounds of financing.

– Investments will be split evenly between the two sectors in which Sofinnova
Partners has specialized since 1989: information technology and life sciences.

– In line with Sofinnova Partners’ strategy, the new fund will concentrate
its investments in ambitious projects and companies being formed or in their
early stage of development.

– In the information technology field, Sofinnova Partners will focus on
financing projects related to network technologies, a market expected to attract
two thirds of all information technology investments between now and 2004.

– In life sciences, Sofinnova Capital IV will continue to concentrate its
investments in two vital fields: biopharmaceutical projects directed at major
pathologies such as central nervous system disorders, infectious diseases and
cancer, and medical instrumentation projects that are likely to set new
international standards.

– Sofinnova Capital IV will be 50% invested in France, 35% in other European
countries and 15% in the US.

Six investments have already been made

Sofinnova Partners has already made six investments on behalf of the new

. Four are in the life sciences sector:

->Neuro 3D, a French company developing compounds for the treatment of
disorders of the central nervous system, which Sofinnova Partners financed at
the seed stage and for which it was co-leader of the first financing round in
November 2000 (EUR 1.3 million).

->Cellzome, a German company in which Sofinnova Partners invested EUR 5.6
million in February 2001, specialized in proteomics and a spin-off from the
prestigious EMBL research center in Heidelberg.

->Biolipox, a Swedish company specialized in the discovery and development
of new therapeutic compounds for use in the treatment of respiratory diseases.
Sofinnova Partners was the co-leader for the first financing round, which raised
EUR 2.3 million in March 2001.

->David Pharmaceuticals, a US company specialized in the development of
new therapeutic compounds for use in the treatment of memory disorders.
Sofinnova Partners invested EUR 3.3 million as co-lead investor with Sofinnova
Ventures in San Francisco.

. Two investments are in the information technologies field:

->E-mail Vision, a French company that provides software platforms for
implementing direct marketing campaigns on the Internet. Sofinnova partners
invested EUR 3.5 million in March 2001 as leader of a new financing round.

->T-Source, a new seed fund specialized in telecommunications and formed
by I-source Gestion. Sofinnova Partners invested EUR 2 million in March 2001.
Sofinnova Partners, which traces its origins back to 1972, is managed by a
close-knit team of seven investment specialists with complementary skills, drawn
from extremely diverse backgrounds and organized into two specialized groups
(life sciences and information technology). This team draws on a quality
European network of partner-investors and on its natural partner in the US,
Sofinnova Ventures in San Francisco, for its international development. It
currently manages EUR 500 million of assets.


E-Mail Vision lève 7,25 millions d’euros pour son 3ème tour de table

La société se donne les moyens de renforcer son leadership sur le marché
européen du e-mail marketing externalisé

E-Mail Vision, le leader européen des solutions e-mail marketing, vient de
boucler un des plus importants tour de table de ce début d’année 2001. Deux
nouveaux investisseurs, SOFINNOVA PARTNERS et la SPEF ont rejoint les
investisseurs historiques, ABN AMRO CAPITAL et APOLLO INVEST pour apporter
ensemble plus de 7 millions d’euros. Cette injection de capital permettra à
E-Mail Vision d’atteindre la rentabilité et de consolider sa position de leader
sur le marché européen. Six millions d’euros ont déjà été injectés dans le
capital de cette entreprise depuis sa fondation, en mai 1999.

” Le e-mail marketing, lorsqu’il est réalisé par des spécialistes, constitue
aujourd’hui un canal de marketing à fort retour sur investissement pour les
entreprises “, déclare Nick Heys, fondateur et CEO d’E-Mail Vision. ” Pionniers
sur le marché Européen, nous avons mis en place les infrastructures
technologiques les plus performantes et une équipe de professionnels des plus
qualifiée en Europe. Cette levée de fonds nous donne les moyens d’affirmer notre
position de leader sur le marché européen “, ajoute Nick Heys.

E-Mail Vision met à disposition de ses clients une application 100 % web et
une infrastructure technologique leur permettant de gérer, personnaliser et
assurer le suivi de leurs campagnes de permission e-mail marketing. Il offre
également une gamme complète de services de production et de conseil pour les
sociétés souhaitant un service global.

” Nous sommes ravis d’accueillir SOFINNOVA PARTNERS et la SPEF au sein de
notre capital et conseil de direction. Ces investisseurs prestigieux nous
apportent leur expérience et leur carnet d’adresses que nous comptons utiliser
pour démultiplier l’essor de notre activité. Nous sommes également heureux de la
confiance qu’ABN AMRO et APOLLO INVEST ont décidé de nous renouveler “, explique
Nick Heys.

Alain Rodermann, partenaire associé de SOFINNOVA PARTNERS (sofinnova.social-unit.fr) explique pour sa part : ”
Nous sommes fiers d’ajouter E-Mail Vision à notre portefeuille d’investissements
et allons nous employer à aider activement l’équipe E-Mail Vision à bâtir une
société solide sur ce nouveau marché. Notre choix d’investissement nous a été
largement dicté par la confiance que nous accordons à la fois au business model,
à la technologie et aux managers qui composent la société. ”

Marco de Alfaro, directeur associé de SPEF e-FUND (www.spef.fr) ajoute quant à lui : ” Nous sommes
très enthousiastes concernant notre investissement dans E-Mail Vision qui
s’inscrit dans plusieurs tendances que nous observons, comme le marketing direct
et l’ASP. Nous pensons que cette entreprise est positionnée de façon unique pour
bénéficier en premier de l’énorme croissance de la demande des sociétés
européennes en matière de technologies et de services d’e-mail marketing.”

Bernard Louis Roques, partenaire associé de ABN AMRO VENTURE commente : ”
E-Mail Vision dispose désormais d’une solide plate-forme d’investisseurs et des
moyens qui lui permettront de construire des barrières aux nouveaux entrants sur
ce marché tout en y renforçant sa position de leadership. “. Enfin, Laurent
Asscher, CEO d’APOLLO INVEST conclut : ” Rien ne s’oppose plus maintenant à ce
qu’E-Mail Vision rafle la mise sur un marché de plus en plus globalisé. “

La société E-Mail Vision a été conseillée par Valluet Achache & Associés
et ABN Amro Corporate Finance.

A propos d’E-Mail Vision Créée en France en mai 1999, E-Mail Vision (www.emailvision.com) propose une
plate-forme technologique sous forme d’ASP (Application Service Provider) ainsi
que des services complets de gestion de campagnes de marketing direct par
e-mails. La solution E-Mail Vision permet aux entreprises de fidéliser leurs
clients à des coûts exceptionnellement bas par rapport aux méthodes de marketing
direct classiques. A l’opposé du ” Spam “, le ” permission e-mail marketing ”
consiste à envoyer des campagnes par e-mail à des individus qui ont
préalablement donné leur accord. Ces campagnes peuvent prendre la forme de
newsletters, d’alertes ou d’offres commerciales personnalisées selon le profil
du client. E-Mail Vision dispose d’une solide base de clients dont MTV, Médecins
sans Frontières, Le Club des Créateurs de Beauté (L’Oréal), Louis Vuitton,
Chapitre.com, Bouygues Telecom, e-TF1, Dell et Décathlon. E-Mail Vision a en
outre noué des partenariats commerciaux avec des agences Web et de marketing
direct tels que Publicis Dialog, Direct One et Icon Medialab.

Visit website http://www.emailvision.com


E-Mail Vision raises 7.25 Million Euros in series C round Company now
positioned for European leadership in outsourced e-mail marketing services

E-Mail Vision (www.emailvision.com)
the leading European e-mail marketing services company with headquarters in
Paris, France has raised over 7 million Euros in its series C round. New
investors SOFINNOVA PARTNERS and SPEF joined current investors ABN AMRO CAPITAL
and APOLLO INVEST in the private placement. The company, founded in May 1999 by
Nick Heys, stated that the capital will see it through to profitability and
enable it to consolidate its leadership position in the European marketplace.
The company has previously raised over 6 Million Euros.

“E-mail marketing, when done right, is now a proven high return on investment
channel for marketers”, declared Nick Heys, Founder & CEO of E-Mail Vision.
As first movers, we have built the most advanced technology infrastructure and
most experienced professional services team in Europe. With this new round of
funding we are now uniquely positioned for leadership in the European market”.

E-Mail Vision offers clients a powerful web based application and technology
infrastructure to manage, personalise, deliver and track permission e-mail
marketing campaigns. It also offers a complete range of production, consulting
and database services for companies seeking a full service solution.

“We are delighted to add SOFINNOVA PARTNERS and SPEF to our investor base and
board of directors. These prestigious investors bring a wealth of experience and
contacts which we intend to leverage in building our business. We are also
pleased that APOLLO INVEST and ABN AMRO re-invested in this round showing
continued commitment to our business and management team” said Nick Heys.

Alain Rodermann, partner at SOFINNOVA PARTNERS (sofinnova.social-unit.fr) said “we are pleased to
have added E-Mail Vision to our investment portfolio and look forward to
supporting the management team in building a great company in this new market.
Our investment decision was driven by our belief in the E-Mail Vision business
model, technology and experienced management team”.

Marco de Alfaro, director of SPEF e-FUND (www.spef.fr) added. “We are very excited about our
investment in E-Mail Vision, which fits with several key trends that we see,
such as direct marketing and ASP. We believe this company is uniquely positioned
to benefit from the huge growth in demand for outsourced e-mail marketing
systems and services in Europe”.

Bernard Louis Roques, partner at ABN AMRO VENTURE said “E-Mail Vision now has
a strong investor base and the means to continue building barriers to entry and
maintain its leadership position in Europe”.

Laurent Asscher, CEO of APOLLO INVEST added “E-Mail Vision is now extremely
well prepared to compete and win in an increasingly global marketplace”. E-Mail
Vision was assisted by ABN Amro Corporate Finance and Cabinet Valluet-Achache
& Associés in completing this C Round.

Visit website http://www.emailvision.com


Bernard Gilly, ancien Directeur Général de Transgène, rejoint l’équipe des Sciences de la Vie de Sofinnova Partners, animée par Denis Lucquin et Antoine Papiernik, en qualité de partenaire-associé.

Sofinnova Partners, pionnier du capital risque en France, est un des leaders européens de son secteur dans les domaines des sciences de la vie et des technologies de l’information.

Bernard Gilly, 44 ans, ingénieur agronome, docteur en économie et diplômé de l’Insead, a débuté sa carrière en 1980 à l’Inra et à l’Ifremer avant de rejoindre Pasteur Mérieux comme directeur adjoint de la Recherche en 1990. Nommé Directeur Général de Transgène en 1992, il refonde l’entreprise et en fait très rapidement un des leaders mondiaux de la thérapie génique, avant de l’introduire avec succès simultanément au Nouveau Marché de la Bourse de Paris et au Nasdaq de New York en mars 1998. Parallèlement, Bernard Gilly a occupé de 1994 à juillet 1997, les fonctions de Directeur de la Recherche de BioMérieux, actionnaire de référence de Transgène. Il a quitté Transgène fin novembre 2000 pour rejoindre Sofinnova Partners. Il est par ailleurs membre des Conseils d’Administration de l’INSERM et de l’Ecole Normale Supérieure de Lyon. Co-fondateur de France-Biotech, Bernard Gilly est très impliqué dans l’émergence et le développement en France de nouvelles entreprises utilisant les hautes technologies : membre du Comité Directeur de Croissance Plus, il participe aux Conseils d’Administration de Wavecom (entreprise cotée sur le Nouveau Marché, spécialiste des modules intégrés pour les télécommunications), de HighDeal (start-up créée en février 2000, spécialiste de la gestion de la chaîne de valeur sur internet). Il est également Président et co-fondateur de WebSurg, une start-up spécialisée dans l’e-training et l’éducation des chirurgiens et des professions para-chirurgicales.

” Je me réjouis de rejoindre aujourd’hui une équipe appréciée et reconnue pour son professionnalisme et son implication auprès des porteurs de projet” a affirmé Bernard Gilly. “Je souhaite concentrer mes efforts sur la détection précoce de projets d’entreprises innovantes, afin de les aider à se positionner et à se développer rapidement “.

Jean-Bernard Schmidt, Président de Sofinnova Partners, a déclaré : “L’arrivée de Bernard Gilly au sein de notre équipe va considérablement renforcer nos moyens d’actions à l’échelle européenne ; son expérience de chercheur, puis de manager et développeur d’une des plus belles entreprises de biotechnologie européennes va nous être précieuse pour accroître notre capacité à identifier et faciliter l’éclosion des meilleurs projets d’entreprise dans le secteur des Sciences de la Vie. ”

Basée à Paris, l’équipe de Sofinnova Partners réunit aujourd’hui 7 partenaires-associés et gère près de 3 MdF. S’agissant des Sciences de la Vie, Sofinnova Partners privilégie les investissements au stade de la création dans la biopharmacie et l’instrumentation médicale. Ainsi Sofinnova Partners a notamment été investisseur fondateur dans des entreprises comme GENSET, CEREP, NICOX, ACTELION et NOVUSPHARMA. Dans les Technologies de l’Information, ses investissements portent essentiellement sur les technologies Internet et télécom, les logiciels applicatifs et la micro-électronique. Depuis 1996, Sofinnova Partners a réalisé 50 investissements dont 31 comme chef de file. Elle siège à ce jour aux Conseils d’Administration de 27 d’entre eux et continue ainsi à leur apporter un soutien actif. Sofinnova Partners étudie chaque année entre 1000 et 2000 nouveaux dossiers d’investissement.


Bernard Gilly, former President and Chief Executive Officer of Transgene, is joining Denis Lucquin and Antoine Papiernik as partner in the Life Sciences team of Sofinnova Partners.

Sofinnova Partners, a venture capital pioneer in France, is a European leader in the areas of life sciences and communication technologies.

Bernard Gilly, aged 44, is an agronomist, a Doctor of Economics and holds a MBA from INSEAD. He began his career in 1980 at Inra and Ifremer before joining Pasteur Mérieux as Associate Director of Research in 1988. Appointed Managing Director of Transgene in 1992, he completely overhauled the company and rapidly made it a world leader in gene therapy, before successfully launching it simultaneously onto the Nouveau Marché of the Paris Stock Exchange and the New York NASDAQ in March 1998. Simultaneously, from 1994 to July 1997, Bernard Gilly was VP Research and Development of BioMérieux, the major stockholder of Transgene. He left Transgene at the end of November 2000 to join Sofinnova Partners. He is also a member of the Governing Boards of INSERM (French National Medical Research Institute) and the Ecole Normale Supérieure de Lyon. Co-founder of France-Biotech, Bernard Gilly has been extensively involved in the emergence and development in France of new companies using advanced technologies: member of the Steering Committee of Croissance Plus, he participates in the Boards of Wavecom (a French company quoted on the Nouveau Marché, specializing in telecom integrated modules) and HighDeal (start-up created in February 2000, specializing in the management of value-added chain on the Internet). He is also President and co-founder of WebSurg, a start-up specializing in education and e-training of surgeons and para-surgical professions on the Internet.

“I am very happy today to be joining a skilled team esteemed and respected for its professionalism and involvement with start up companies” said Bernard Gilly. “I will focus my efforts on the early discovery of innovative companies, so as to help them establish their position and quickly develop as leaders in their own field”.

Jean-Bernard Schmidt, President of Sofinnova Partners, stated:”The arrival of Bernard Gilly in our team will considerably strengthen our position on a European level. His experience as a researcher, then manager and developer of one of the finest European biotechnology companies, will be of great value to us in enhancing our ability to identify and facilitate the germination of the best company projects in the Life Sciences sector”.

Based in Paris, the Sofinnova Partners team now consists of 7 partners, managing close to 3 billion French francs. Regarding Life Sciences, Sofinnova Partners is an early stage investor in biopharmaceutical and medical devices. Sofinnova Partners has been in particular a founding investor in companies such as GENSET, CEREP, NICOX, ACTELION and NOVUSPHARMA. Its investments in Information Technologies have essentially concerned Internet and telecoms, application software and micro-electronics. Since 1996, Sofinnova Partners has made 50 investments, including 31 as lead investor. It currently sits on the boards of 27 of them and hence continues to provide active support. Sofinnova Partners evaluates each year between 1000 and 2000 new investment proposals.